Adial Pharmaceuticals, Inc (ADIL) Financial Statements (2023 and Earlier)

Company Profile

Business Address 1180 SEMINOLE TRAIL
CHARLOTTESVILLE, VA 22901
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments6,0624,4016,7773,869
Cash and cash equivalents6,0624,4016,7773,869
Prepaid expense10233831506
Intangible current assets 11 
Other undisclosed current assets39050164318
Total current assets:6,4625,1367,6734,693
Noncurrent Assets
Operating lease, right-of-use asset246  
Property, plant and equipment58   
Intangible assets, net (including goodwill)2546  
Goodwill249   
Intangible assets, net (excluding goodwill)56  
Other noncurrent assets  67
Other undisclosed noncurrent assets455350  
Total noncurrent assets:1,01335667
TOTAL ASSETS:7,4755,4917,6804,699
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,6631,505539258
Accounts payable286649190 
Accrued liabilities2,377857349 
Other undisclosed accounts payable and accrued liabilities   258
Debt50   
Other liabilities10   
Total current liabilities:2,7221,505539258
Noncurrent Liabilities
Long-term debt and lease obligation207   
Operating lease, liability207  
Liabilities, other than long-term debt23   
Deferred income tax liabilities23  
Other undisclosed noncurrent liabilities1,014   
Total noncurrent liabilities:1,245   
Total liabilities:3,9671,505539258
Stockholders' equity
Stockholders' equity attributable to parent3,5083,9867,1414,441
Common stock2114107
Additional paid in capital54,43035,49127,75716,470
Accumulated deficit(50,943)(31,520)(20,627)(12,035)
Total stockholders' equity:3,5083,9867,1414,441
TOTAL LIABILITIES AND EQUITY:7,4755,4917,6804,699

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues46376  
Other operating income 376  
Other income46   
Cost of revenue
(Financing Interest Expense)
   (1,167)
Gross profit:46376 (1,167)
Operating expenses(19,289)(10,928)(8,245)(6,987)
Other undisclosed operating income (loss)(46)(376) 1,167
Operating loss:(19,289)(10,928)(8,245)(6,987)
Nonoperating income (expense)(229)35(347)(4,644)
Investment income, nonoperating(275)32957
Interest and debt expense   (5)
Loss from continuing operations before equity method investments, income taxes:(19,517)(10,893)(8,591)(11,636)
Other undisclosed income from continuing operations before income taxes   5
Loss from continuing operations before income taxes:(19,517)(10,893)(8,591)(11,631)
Income tax expense (benefit)94446(14,246) 
Loss before gain (loss) on sale of properties:(19,423)(10,447)(22,838)(11,631)
Other undisclosed net income (loss) (446)14,246 
Net loss available to common stockholders, diluted:(19,423)(10,893)(8,591)(11,631)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(19,423)(10,893)(8,591)(11,631)
Comprehensive loss, net of tax, attributable to parent:(19,423)(10,893)(8,591)(11,631)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: